Bharat Biotech’s nasal COVID-19 Vaccine candidate obtained regulatory approval for mid-to late-stage trials, said the government’s ministry of science and technology. Early-stage trials of the vaccine candidate, BBV154, have been accomplished in participants aged 18 to 60 years, and the doses were found to be well-tolerated.
The biotech company’s COVAXIN, COVID-19 Vaccine is approved for emergency use in the country, is administered through an injection. Renu Swarup, chairperson of the Biotechnology Industry Research Assistance Council. Said that the company’s BBV154 Covid Vaccine is the first intranasal vaccine being developed in the country entering into late-stage clinical trials.
The Delta variant has been classified by the World Health Organization (WHO) as a variant of concern. Apart from triggering India’s second Covid-19 wave during March-May, it is estimated to have caused 90% of the cases India reported the variant has been found in nearly 99 countries. More infectious than the Alpha, Beta, and Gamma variants, it is the leading cause of breakthrough infections in vaccinated individuals across the globe.